Impact of Donor and Recipient CMV Status on Infection After Kidney Transplant
Author Information
Author(s): David Hughes, John Hafferty, Lee Fulton, Peter Friend, Andrea Devaney, Justin Loke, Ken I. Welsh, Ashok Handa, Paul Klenerman
Primary Institution: Nuffield Department of Surgery, John Radcliffe Hospital, Oxford
Hypothesis
What is the impact of recipient serostatus on the risk of CMV antigenemia in renal transplant patients?
Conclusion
Donor serostatus significantly influences CMV risk even in seropositive recipients.
Supporting Evidence
- 35% of patients experienced CMV antigenemia during the follow-up period.
- Antigenemia was most common in seronegative recipients of organs from seropositive donors.
- The risk of infection was significantly higher in recipients of D+ organs compared to Dā organs.
Takeaway
This study shows that the type of kidney donor can affect how likely a transplant patient is to get a virus called CMV, even if they have some immunity.
Methodology
The study prospectively quantified CMV antigenemia in 486 renal transplant recipients and analyzed it based on donor and recipient serostatus.
Potential Biases
There may be risks of bias related to the selection of patients and the interpretation of serostatus.
Limitations
The study may have limitations related to the accuracy of serostatus testing and the potential for nosocomial infections.
Participant Demographics
The cohort included 486 renal transplant recipients with varying donor and recipient CMV serostatus.
Statistical Information
P-Value
0.006
Confidence Interval
1.28ā3.91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website